Unicharm (8113) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
7 Jul, 2026Executive summary
Achieved record-high sales and core operating income for the eighth consecutive year, driven by value-shifting, cost reductions, and strong performance in personal care, pet care, and other businesses across all regions.
Gross profit margin improved significantly, with strong growth in both Japan and overseas markets, especially in Asia and North America.
Dividend increased for the 23rd consecutive year, with a planned total return ratio of 50% through dividends and share buybacks.
Continued focus on sustainability initiatives, launching recycled and eco-friendly products in multiple segments.
Financial highlights
Consolidated sales for Jan–Jun 2024: ¥487.7 billion (YOY +7.4%), core operating income: ¥73.1 billion (YOY +24.4%), EBITDA: ¥96.2 billion (YOY +17.8%).
Profit before tax: ¥73.4 billion (YOY +20.3%), net income attributable to owners: ¥39.6 billion (YOY +14.3%), EPS: ¥67.27 (YOY +15.1%).
Gross profit margin improved by 3.5 points; sales and core operating income reached new quarterly highs.
Total comprehensive income: ¥99.18 billion (up from ¥81.41 billion YOY).
Foreign exchange fluctuations contributed ¥26.9 billion to sales and ¥3.5 billion to core operating income.
Outlook and guidance
FY2024 sales forecast: ¥1,006 billion (YOY +6.8%), core operating income: ¥144 billion (YOY +12.5%), profit attributable to owners forecast: ¥90 billion (YOY +8.8%).
Dividend forecast for FY2024: ¥44.00 per share (up from ¥40.00 in FY2023).
Second-half sales and profit expected to increase, with continued focus on value-shifting, cost absorption, and product innovation.
Latest events from Unicharm
- Record sales and profit growth, but profit guidance cut amid cost pressures and global risks.8113
Q2 2026 - Q1 FY2026 saw higher sales and profit, but net profit fell due to lower other income.8113
Q1 2026 - Profits fell in FY2025, but FY2026 forecasts strong recovery and higher dividends.8113
Q4 2025 - Sales and core profit declined, but profit attributable to owners rose 2.0% YoY.8113
Q3 2025 - Sales and profits fell, but resilient regions and cost controls support a recovery outlook.8113
Q2 2025 - Record sales and profit growth, with strong personal and pet care and rising dividends.8113
Q3 2024 - Net profit jumped in Q1 FY2025 despite lower sales, aided by insurance proceeds.8113
Q1 2025 - Record sales and profit growth, with a stock split and strong FY2025 outlook.8113
Q4 2024